Cor/Schering Integrilin Revenue Recovery Projected After Label Change
Executive Summary
Cor Therapeutics expects Integrilin efficacy data and the co-promotional deal with Genentech will help the company recover from the recent inventory drawdown of the peptide glycoprotein IIb/IIIa receptor antagonist.